CytomX Therapeutics (NASDAQ: CTMX) reported Q3 EPS of ($0.09), $0.04 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $11.84 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.